<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Curr Neuropharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Neuropharmacol</journal-id>
<journal-id journal-id-type="publisher-id">CN</journal-id>
<journal-title-group>
<journal-title>Current Neuropharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1570-159X</issn>
<issn pub-type="epub">1875-6190</issn>
<publisher>
<publisher-name>Bentham Science Publishers</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29701156</article-id>
<article-id pub-id-type="pmc">7059152</article-id>
<article-id pub-id-type="publisher-id">CN-17-672</article-id>
<article-id pub-id-type="doi">10.2174/1570159X16666180426151746</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Diagnostic Issues in Early-Onset Obsessive-Compulsive Disorder and their Treatment Implications</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Burchi</surname>
<given-names>Elisabetta</given-names>
</name>
<xref ref-type="aff" rid="aff1">a</xref>
<xref ref-type="aff" rid="aff2">b</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pallanti</surname>
<given-names>Stefano</given-names>
</name>
<xref ref-type="aff" rid="aff1">a</xref>
<xref ref-type="aff" rid="aff3">c</xref>
<xref ref-type="aff" rid="aff4">d</xref>
</contrib>
<aff><target id="aff1" target-type="aff"><sup>a</sup></target>Department of Scienze della Salute, <institution>University of Florence</institution>, <addr-line><city>Florence</city></addr-line>, <country>Italy</country>; <break></break>
<target id="aff2" target-type="aff"><sup>b</sup></target>Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY, <country>USA</country>;<break></break>
<target id="aff3" target-type="aff"><sup>c</sup></target>Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, CA, <country>USA</country>;<break></break>
<target id="aff4" target-type="aff"><sup>d</sup></target>Institute of Neuroscience, <addr-line><city>Florence</city></addr-line>, <country>Italy</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>Address correspondence to this author at the Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine and Montefiore Medical Center 111 East 210th street, Bronx, NY, 10467, USA;, Tel: 929-308-6669; E mail: <email xlink:href="bettina.burchi@gmail.com">bettina.burchi@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2019</year>
</pub-date>
<volume>17</volume>
<issue>8</issue>
<fpage>672</fpage>
<lpage>680</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>1</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>16</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>4</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 Bentham Science Publishers</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/legalcode">
<license-p> This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (<uri xlink:href="https://creativecommons.org/licenses/by-nc/4.0/legalcode">https://creativecommons.org/licenses/by-nc/4.0/legalcode</uri>), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>The lifespan approach and recent shift in the conceptualization of Obsessive-Compulsive Disorder (OCD) promoted by the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM5) along with novel insights into the pathogenesis of this heterogeneous disorder are driving the development of new outcome measures and new treatments for a disease that, on the other hand, is characterized by high rates of refractoriness.</p>
</sec>
<sec>
<title>Objective and Methods</title>
<p>The aim of this review is to provide a discussion of the translational 
evidence about Early Onset OCD (EO) in compliance with a neurodevelopmental and RdoC perspective.</p>
</sec>
<sec>
<title>Results and Conclusion</title>
<p>EO might be considered the neurodevelopmental subtype of OCD. Indeed there is evidence that different clusters of symptoms and dimensions at an early stage predict different trajectories in phenotype and that distinct neurocircuit pathways underpin the progression of the disorder. Despite the development of high refractoriness in the course of the disorder, evidence suggests that EO may be particularly treatment responsive in the early stages, thus showing the need for early recognition and additional recovery oriented studies in this subgroup.</p>
<p>Consistent with the neurodevelopmental perspective, immunity and glutamate neurotransmission are emerging as novel pathways for parsing out the neurobiology of OCD, the EO form, in particular, supporting the implementation of new multisystemic models of the OCD phenotype. Brain connectivity patterns, immune and microbiome profiles are standing out as promising areas for biomarkers with the potential for targeted personalized therapies in EO.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Early-onset OCD</kwd>
<kwd>pediatric OCD</kwd>
<kwd>neurodevelopmental disorders</kwd>
<kwd>neuroinflammation</kwd>
<kwd>glutamatergic agents</kwd>
<kwd>gut microbiome</kwd>
<kwd>RDoC</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1" sec-type="intro">
<label>1</label>
<title>INTRODUCTION</title>
<p>Obsessive-compulsive disorder (OCD) with a lifetime prevalence ranging from 1.5% to 3.5% [<xref ref-type="bibr" rid="r1">1</xref>] is an important cause of disability among brain disorders [<xref ref-type="bibr" rid="r2">2</xref>]. The burden of disease conveyed by this condition is related to its early onset [<xref ref-type="bibr" rid="r3">3</xref>, <xref ref-type="bibr" rid="r4">4</xref>] and high degree of refractoriness [<xref ref-type="bibr" rid="r5">5</xref>] and call for the implementation of studies that yield biosignatures to stratify the broad-illness phenotype into a finite number of treatment relevant subgroups.</p>
<p>There is evidence that age-of-onset constitutes a useful variable for parsing the obsessive-compulsive (OC) phenotype</p>
<p>[<xref ref-type="bibr" rid="r6">6</xref>]. According to latent class analysis, early onset OCD (EO) represents a distinct subgroup (mean onset 11 years) and the most common form of the disorder compared to a later onset subtype (LO), with 21 years as empirically defined cutoff [<xref ref-type="bibr" rid="r7">7</xref>]. Multiple meta-analysis indicate that EO and LO could be reliably distinguished in terms of gender distribution, clinical features and genetic load [<xref ref-type="bibr" rid="r7">7</xref>], with EO presenting higher prevalence in males, higher level of comorbidity with tics and other OC spectrum disorders, higher genetic heritability [<xref ref-type="bibr" rid="r8">8</xref>] and higher global OCD severity [<xref ref-type="bibr" rid="r9">9</xref>], not only justified by the longer duration of illness [<xref ref-type="bibr" rid="r10">10</xref>]. On the other hand, the two putative subtypes seem not to differ significantly in terms of the factor structure of symptoms, which tend to co-occur together [<xref ref-type="bibr" rid="r11">11</xref>, <xref ref-type="bibr" rid="r12">12</xref>].</p>
<p>Mega-analysis of neuroimaging data indicates different patterns of subcortical abnormalities in pediatric versus adult OCD patients [<xref ref-type="bibr" rid="r13">13</xref>], with thalamus implicated in pediatric OCD and pallidum and hippocampus in adult OCD. Stratified analyses showed that adult OCD patients with an early disease-onset exhibit larger pallidum volumes than controls, hypothesizing that it could be related to the progression of EO. On the other hand, the clear distinction in thalamic 
volume across pediatric and adult OCD patients suggests that an increased thalamic volume may be an early marker of altered neurodevelopment in EO. The same morphological characteristic has been found in patients diagnosed with other neurodevelopmental disorders, such as ADHD [<xref ref-type="bibr" rid="r14">14</xref>] and Tourette’s syndrome [<xref ref-type="bibr" rid="r15">15</xref>] and notably, an early pharmacological treatment has been suggested to have a normalizing effect on thalamus volume in pediatric OCD [<xref ref-type="bibr" rid="r16">16</xref>].</p>
<p>Although research is still needed to determine the optimal criteria for establishing age of onset and whether EO and LO differ in their biology, the fact that OCD tends to present its onset in pre-adult age support the appropriateness of a research and clinical approach towards OCD and specifically EO that take into account the neurodevelopmental perspective [<xref ref-type="bibr" rid="r17">17</xref>].</p>
</sec>
<sec id="sec2" sec-type="other1">
<label>2</label>
<title>EO: A NEURODEVELOPMENTAL DISORDER. DIMENSIONS AND TRAJECTORIES.</title>
<p>The high heterogeneity and degree of comorbidity reported by OCD patients support the need for dimensionally dissecting the OCD phenotype. From a neurodevelopmental perspective, EO constitutes the subtype of choice for using this quantitative approach, thus driving the identification of more robust endophenotypes [<xref ref-type="bibr" rid="r18">18</xref>].</p>
<p>Although OCD affects approximately 0.5 to 2.0% of children, subclinical OC symptoms are present in around 10%-15% of the pediatric population [<xref ref-type="bibr" rid="r19">19</xref>, <xref ref-type="bibr" rid="r20">20</xref>] and they have been found to predict the development of full OCD and other psychiatric comorbidities later in life [<xref ref-type="bibr" rid="r21">21</xref>]. Due to the fact that in the early stage symptoms are often hard to be attributed exclusively to a specific category of disorder, there is often a delay in diagnosis of EO [<xref ref-type="bibr" rid="r22">22</xref>] and OCD in these cases is associated with a long duration of untreated illness and long standing developmental impairment, including cognitive features [<xref ref-type="bibr" rid="r23">23</xref>]. On the contrary, earlier diagnosis and treatment are positively related to outcome in EO and some studies found that pediatric OCD remission rates are considerably higher and most durable than in adult samples [<xref ref-type="bibr" rid="r24">24</xref>-<xref ref-type="bibr" rid="r26">26</xref>].</p>
<p>Distinguishing prodromal OCD from physiological developmental behavior may be a critical issue for the clinician. A family history and genetic load seem to be predictors of subsequent progression towards the full disorder [<xref ref-type="bibr" rid="r8">8</xref>]. However, given the evidence that OC symptoms are dimensional rather than categorical in their frequency/severity distributions [<xref ref-type="bibr" rid="r27">27</xref>], it may be beneficial to study non-clinical populations to understand the course of the OC symptoms–OCD continuum and when and how best to intervene. A population-based study [<xref ref-type="bibr" rid="r28">28</xref>] found that three profiles were distinguishable in a sample of school-aged children scoring high on OC symptoms: a subgroup with only OC symptoms, a subgroup with both additional externalizing and internalizing symptoms, and a subgroup with primarily autistic symptoms. Longitudinal follow up of these profiles would help translation towards establishing profiling and staging of the disorder.</p>
<p>On the other hand, prospective categorical studies on clinical samples have shown how OCD does not behave as a unitary disorder, but rather different subgroups can be identified by distinctive lifetime trajectories in comorbidities. A large multicenter study [<xref ref-type="bibr" rid="r29">29</xref>] demonstrated specific associations between first and later comorbid diagnosis in OCD patients, with separation anxiety disorder, ADHD and tic disorders as first comorbid diagnosis predicting respectively additional anxiety and somatoform disorder, higher frequencies of substance abuse and higher lifetime frequencies of OC spectrum disorders in the course of the disorder. Notably, most comorbid disorders in OCD are related to the age of onset of the disorder rather than to the current age: while adolescent-onset OCD patients show higher rates of anxiety and depressive disorders, childhood-onset OCD patients show higher rates of other neurodevelopmental disorders [<xref ref-type="bibr" rid="r30">30</xref>, <xref ref-type="bibr" rid="r31">31</xref>] and this corroborates the importance of a transdiagnostic and multidimensional perspective.</p>
<p>It has been reported that attention-deficit/hyperactivity disorder (ADHD) presents a prevalence estimate of 19% in youth with a primary diagnosis of OCD [<xref ref-type="bibr" rid="r32">32</xref>]. Previous research has also found that comorbid ADHD may interfere with success in OCD treatment, with poorer treatment outcomes in cognitive behavioral therapy (CBT) [<xref ref-type="bibr" rid="r33">33</xref>]. However, a recent study [<xref ref-type="bibr" rid="r34">34</xref>] has found that when treating a child or adolescent with co-occurring OCD and clinically significant attention problems when OCD-onset clearly precedes ADHD-like inattention, clinicians may wish to target obsessive-compulsive symptoms first to have also inattention improved.</p>
<p>A high prevalence of autistic traits has been found in OCD samples both in adults and in children [<xref ref-type="bibr" rid="r35">35</xref>] and comorbidity between autism spectrum disorder (ASD) and OCD may significantly affect treatment outcome [<xref ref-type="bibr" rid="r36">36</xref>]. One study [<xref ref-type="bibr" rid="r37">37</xref>] associated the poorer response to CBT in OCD to abnormalities in the left dorsolateral prefrontal cortex (DLPFC) that may be also associated with autistic traits.</p>
<p>As concern comorbidity between OCD and tic disorders (TD), it is so frequent in a specific subgroup of patients that many experts believe that the two disorders represent a specific subtype of the illness, which might be referred to as Obsessive-Compulsive Tic Disorder (OCTD), the further elaboration of the DSM-5 OCD tic-related specifier [<xref ref-type="bibr" rid="r38">38</xref>-<xref ref-type="bibr" rid="r40">40</xref>]. Available literature [<xref ref-type="bibr" rid="r41">41</xref>] suggests that OCTD is characterized by early onset, male gender, sensory phenomena and obsessions of symmetry, aggressiveness, hoarding, exactness and sounds, impulsive behaviors and ADHD comorbidity.</p>
<p>It has been argumented that this putative subtype could be particularly resistant to pharmacological treatment [<xref ref-type="bibr" rid="r41">41</xref>], requiring combination/augmentation treatment with serotonin reuptake inhibitors (SRIs) plus antipsychotics at the highest tolerated dosage. However, although tic disorders have shown to adversely impact the outcome of serotonin reuptake inhibitors use in pediatric OCD, CBT outcomes seem to be not impacted by comorbid tic disorders [<xref ref-type="bibr" rid="r42">42</xref>, <xref ref-type="bibr" rid="r43">43</xref>].</p>
<p>Increasing evidence found that the phenotypical heterogeneity observed across the EO subgroup and in the same patient in the course of the disorder is associated with likewise neurobiological complexity.</p>
<p>Moreover, recent studies found that the co-occurrence of OC symptoms, tics and attention-deficit/hyperactivity symptoms can be only partly explained by shared pathogenetic pathways and there is still need for longitudinal dimensional studies that examine subdimensions and identify more genetically homogenous symptom subtypes [<xref ref-type="bibr" rid="r44">44</xref>]. The need for further dissecting the EO phenotype is confirmed by the significant variability in how well children and adolescents with OCD respond to CBT and SSRI [<xref ref-type="bibr" rid="r45">45</xref>].</p>
<p>Current practice guidelines for pediatric OCD, recommend using CBT monotherapy in patients with mild to moderate symptom severities and combined SSRI e CBT treatment for more severe cases [<xref ref-type="bibr" rid="r46">46</xref>] or when the patient has not shown adequate response to CBT alone [<xref ref-type="bibr" rid="r47">47</xref>]. But the severity of OCD symptoms seems not be the only factors that should be considered in guiding treatment recommendations. Beyond the unmet need for reliable endophenotypes, the available evidence concerning clinical predictors of response in EO, found that the presence of comorbid tics and a family OCD history may moderate CBT outcomes in this population [<xref ref-type="bibr" rid="r45">45</xref>], and early improvement to SSRIs may predict response [<xref ref-type="bibr" rid="r48">48</xref>] (Table <bold><xref ref-type="table" rid="T1">1</xref></bold>).</p>
</sec>
<sec id="sec3" sec-type="other2">
<label>3</label>
<title>EO: THE IMMUNOLOGICAL ASPECT AND THE ROLE OF GLUTAMATE</title>
<p>From a pathophysiologic perspective, approaching EO as a neurodevelopmental disorder implicates the involvement of microglia and more broadly the immune system as a whole [<xref ref-type="bibr" rid="r49">49</xref>].</p>
<p>The link between OCD and immunity has been brought into light since the 1980s with case series reporting abrupt pre-pubertal onset of OC and tic symptoms occurring in patients with Sydenham's chorea (SC) [<xref ref-type="bibr" rid="r50">50</xref>]. These observations led to the definition of PANDAS [<xref ref-type="bibr" rid="r51">51</xref>] -pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections- and then to the umbrella category of PANS [<xref ref-type="bibr" rid="r52">52</xref>] pediatric acute-onset neuropsychiatric syndrome- where infection seems to be implicated as the primary inciting factor in more than half patients [<xref ref-type="bibr" rid="r53">53</xref>]. Despite the discussion about its existence as a separate entity, PANDAS has constituted a model for autoimmune OCD, developing an immune-driven pathogenetic hypothesis, putative immune biomarkers and specific immunomodulant therapy still waiting support for validation [<xref ref-type="bibr" rid="r54">54</xref>]. Growing evidence is now supporting the fact that immune dysregulation may contribute not only to PANDAS but to the pathophysiology of OCD as a whole [<xref ref-type="bibr" rid="r55">55</xref>, <xref ref-type="bibr" rid="r56">56</xref>]. After all, the neuroinflammatory theory of OCD is in line with the change of paradigm that all psychiatry is coming across and which is based upon the increasing evidence that the crosstalk between the immune system and neurocircuits is pivotal in the pathogenesis of many psychiatric disorders [<xref ref-type="bibr" rid="r57">57</xref>]. Peripheral cytokine alterations profiles have been detected in the majority of psychiatric disorders as well as accumulating evidence indicate that M1-like microglia (proinflammatory) are significantly increased in comparison to ramified microglia (resting) and elongated M2-like microglia (anti-inflammatory) phenotypes in many psychiatric diseases [<xref ref-type="bibr" rid="r58">58</xref>]. A recent study [<xref ref-type="bibr" rid="r56">56</xref>] investigating inflammation in the brain of OCD, has demonstrated the presence of a microglial activation throughout all the cortico-striato-thalamo-cortical (CSTS) circuit, so beyond the basal ganglia which have been implicated in the pathogenesis of PANDAS and beyond the childhood onset. This outstanding study suggests the potential for neuromodulatory drugs that can shift the monocyte/microglia phenotypes, such as azithromycin and minocycline [<xref ref-type="bibr" rid="r59">59</xref>]. The potential usefulness of antibiotic therapy in OCD is as well emerged in the clinical practice, where azhitromycin and beta-lactams – the drugs of choice to treat group A streptococcus (GAS) 
infections – have been extensively used to treat PANDAS patients. A recent review analyzing the evidence supporting this practice-based use [<xref ref-type="bibr" rid="r60">60</xref>], concluded that even if conclusive studies that assess superiority of antibiotics vs placebo in the PANDAS/PANS population are still missing, the available evidence suggests the existence of a pediatric OCD subgroup that goes beyond the boundaries of PANDAS and PANS and that is sensitive to antibiotic therapy, independently of antiinfective activities. Studies have demonstrated that both azhitromycin and beta-lactams molecules confer neuroprotective effects, the first related to its ability to induce M2 polarization in microglia and peripheral macrophages [<xref ref-type="bibr" rid="r61">61</xref>], the second increasing genic expression of glutamate transporter GLT1 and consequently minimizing glutamate neurotoxicity [<xref ref-type="bibr" rid="r62">62</xref>]. This latter effect is particularly relevant considering that converging evidence coming from preclinical [<xref ref-type="bibr" rid="r63">63</xref>, <xref ref-type="bibr" rid="r64">64</xref>] and genetic studies [<xref ref-type="bibr" rid="r65">65</xref>, <xref ref-type="bibr" rid="r66">66</xref>] indicates the importance of glutamate transmission in the pathophysiology of OCD. Although the efficacy of any glutamatergic agents either in combination with selective serotonin reuptake inhibitors or as monotherapy in the treatment of OCD has not yet been established [<xref ref-type="bibr" rid="r67">67</xref>] some data suggest that there might be a subgroup in OCD more sensitive to these agents [<xref ref-type="bibr" rid="r68">68</xref>]. Interestingly, a recent study found that brain glutamate might moderate treatment response to CBT in pediatric OCD [<xref ref-type="bibr" rid="r69">69</xref>].</p>
<p>There is still need for studies concerning glutamatergic agents, especially for pediatric OCD, where just riluzole [<xref ref-type="bibr" rid="r70">70</xref>], D-cycloserine [<xref ref-type="bibr" rid="r71">71</xref>] and NAC [<xref ref-type="bibr" rid="r72">72</xref>] have been investigated in RCTs, with inconclusive results concerning the first two and promising results for the latter.</p>
<p>Independently of the diagnosis, there are preliminary data suggesting the potential use of memantine and N-acetylcysteine (NAC) in the treatment of compulsivity/impulsivity in pediatric patients [<xref ref-type="bibr" rid="r73">73</xref>].</p>
<p>Although we couldn’t find specific studies comparing the effectiveness of memantine in OCD across age groups, it’s been reported that in two cases of refractory OCD treated with an augmentation of memantine [<xref ref-type="bibr" rid="r74">74</xref>], only the case with early onset showed immediate and substantial improvement.</p>
<p>An open label study [<xref ref-type="bibr" rid="r75">75</xref>] conducted in treatment-resistant OCD patients who had failed at least one adequate trial of an antipsychotic in augmentation with an SRI, showed that minocycline augmentation of SRI pharmacotherapy may not improve OCD in all adult OCD patients, but may improve symptoms in those with early-onset OCD and those with primary hoarding. Minocycline, a tetracycline derivative used for chronic acne, next to the anti-inflammatory actions on microglia/macrophages seems to also modulate NMDA-R transmission [<xref ref-type="bibr" rid="r76">76</xref>].</p>
<p>It’s been hypothesized that one putative mechanism of action of glutamatergic agents in OCD could be related to their property to reverse the downstream effects of pro-inflammatory cytokines [<xref ref-type="bibr" rid="r77">77</xref>]. Despite the inconsistent results of previous research about cytokines abnormalities in OCD probably related to confounding effects of medication and comorbid depression, one study conducted in drug naïve comorbidity free OCD patients [<xref ref-type="bibr" rid="r78">78</xref>] found elevated levels of cytokines that - through the kynurenine pathway- may be responsible for alterations in glutamate transmission [<xref ref-type="bibr" rid="r77">77</xref>, <xref ref-type="bibr" rid="r78">78</xref>]. A recent study conducted specifically in pediatric medication-free OCD patients and notably excluding clinically suspected cases with PANDAS/PANS detected an increase in serum TNF-alpha levels compared to unaffected controls [<xref ref-type="bibr" rid="r79">79</xref>].</p>
<p>Another study conducted in pediatric OCD patients found that while there was no difference in basal cytokines production compared to controls, they present a higher percentage of proinflammatory monocytes and enhanced proinflammatory innate response [<xref ref-type="bibr" rid="r80">80</xref>].</p>
<p>If increasing evidence is suggesting that OCD pathogenesis involve immune response, on the other hand effectiveness of SSRIs, the first line of treatment for OCD, may also be mediated by some of the immunomodulatory and anti-apoptotic effects that they have been shown to exert [<xref ref-type="bibr" rid="r81">81</xref>-<xref ref-type="bibr" rid="r83">83</xref>] and that however could be modulated by the quality of the living environment [<xref ref-type="bibr" rid="r84">84</xref>].</p>
<p>One study analyzing drug-similarity based on side effect profiles indicates indeed that some antidepressants and some immune-related drugs may affect common molecular pathways, such as cytokines levels and glucocorticoid signaling [<xref ref-type="bibr" rid="r85">85</xref>].</p>
<p>Two randomized clinical trials [<xref ref-type="bibr" rid="r86">86</xref>, <xref ref-type="bibr" rid="r87">87</xref>] showed the efficacy of anti-inflammatory COX-2 inhibitor celecoxib as an adjunct in the treatment of OCD; it’s been hypothesized that this effect may be mediated by the anti-inflammatory propriety but also by the effect on glutamatergic neurotransmission, seeing that COX-2 inhibitors have been proven to be beneficial in prevention of glutamate-mediated neuronal death [<xref ref-type="bibr" rid="r88">88</xref>].</p>
<p>The complex interplay between brain and immunity leads to consider another actor that may probably play an important role in the pathogenesis of OCD, namely the gut microbiome. There is an extensive literature about the relationship between gut microbiome and brain development and function [<xref ref-type="bibr" rid="r89">89</xref>] and how the immune pathway –through cytokines balance and microglial activation- constitutes an important mechanism of mediation between the two systems. The gut microbiome acts upon the brain through direct and indirect actions, producing neurotransmitters (GABA, serotonin, catecholamines and acetylcholine), and short chain fatty acids that act as neuroimmuneactive substances modulating the Hypothalamic-pituatary-adrenal (HPA) axis, the gut and blood-brain barrier permeability, the production of brain-derived neurotrophic factor (BDNF), and histone deacetylases (HDACs) and microglial activities [<xref ref-type="bibr" rid="r90">90</xref>]. Increasing preclinical evidence corroborates the fact that microbiota plays an important role in neurodevelopment leading to alterations in gene expression and resulting in perturbation to the programming of social and cognitive behaviors [<xref ref-type="bibr" rid="r91">91</xref>]. Evidences have shown how phases of more instability in the composition of gut microbiome –namely perinatal, adolescent and old ages- overlap with the windows of greater vulnerability in brain development [<xref ref-type="bibr" rid="r90">90</xref>]. On the other hand, clinical studies that have characterized the gut microbiome in neuropsychiatric conditions, especially neurodevelopmental, neurodegenerative and mood disorders, found an association with gut microbial dysbiosis [<xref ref-type="bibr" rid="r90">90</xref>].</p>
<p>Although studies specifically concerning microbiome and OCD are still missing [<xref ref-type="bibr" rid="r92">92</xref>], the evidence linking microbiome and neurodevelopmental disorders - particularly autism spectrum disorders and ADHD - and stress-related disorders - as well as the promising results concerning the efficacy of the so called “psychobiotics” in these conditions [<xref ref-type="bibr" rid="r90">90</xref>], suggest that the gut microbiome may convey potential biomarkers and constitute a modifiable factor in the development of OCD. Consistently, probiotic treatment appeared comparable to fluoxetine in attenuating mouse OCD-like behaviors [<xref ref-type="bibr" rid="r93">93</xref>].</p>
<p>Growing evidences are elucidating the interplay of the inflammatory and glutamate pathways in OCD opening the way to identify immune and connectivity biomarkers and subtype this heterogeneous disorder into biologically meaningful component conditions. Although further studies are needed to examine the relationship between cytokines and individual symptom dimensions and to verify if cytokine levels could be predictor of response, evidence support the existence of a subtype of OCD - which probably overlap with EO and supersede the boundaries of PANDAS- that is particularly associated with immune pathophysiology and that would particularly beneficiate of augmentation with immunomodulating and glutamatergic therapies. In the meantime, the complex interplay between brain-immunity and gut in the pathogenesis of OCD drives the implementation of studies aiming to assess the multimodal activities of drugs in the treatment of this population.</p>
</sec>
<sec id="sec4" sec-type="other3">
<label>4</label>
<title>TOWARDS A NEUROBIOLOGICALLY BASED APPROACH</title>
<p>The intersystemic pathogenesis and neuro-developmental progression of EO calls for the implementation of targeted and real-time approaches that take into account the clinical staging of the disorder in the single patient.</p>
<p>The challenge of parsing out the heterogeneity of OCD and EO is finally in the hands of the Research Domain Criteria (RDoC) project [<xref ref-type="bibr" rid="r94">94</xref>], that following an individual-centric approach constitutes the framework to inform Big Data coming from genomics, physiology, psychopharmacology, system biology and behavioral science, then constituting the roadmap for the realization of the claims of Precision Psychiatry.</p>
<p>Based upon the paradigm of mental disorders as disorders of brain circuitries, the circuit level becomes the pivotal level of analysis and the most promising field in order to individuate biomarkers.</p>
<p>Several preclinical and clinical studies have uncovered substantial evidence that dysfunction in cortico-striatal-thalamo-cortical (CSTC) loops may underlie compulsive behavior [<xref ref-type="bibr" rid="r95">95</xref>]. Over the past 5 years, optogenetic studies have led to great progress in further dissecting these neural circuits and argue that multiple paths may subtend perseverative behavior – <italic>i.e</italic>. through dysfunction of either habit system or goal-directed/limbic system [<xref ref-type="bibr" rid="r96">96</xref>].</p>
<p>However, an individual-specific approach is critical in identifying biomarker and there is still need for implementing studies that detect functional brain circuit connections that track changes in global and dimension-specific symptom severity longitudinally, in the same patient. Recently, one study conducted in OCD patients [<xref ref-type="bibr" rid="r97">97</xref>] found that changes in connectivity pre-post treatment in the individual patient can predict YBOCS improvement, while connectivity was less predictive in template-based comparisons.</p>
<p>The individuation of connectivity biomarkers and the anatomical characterization of individuals may promote identification of new outcome measures and true integration between psychopharmacology, psychotherapy and neuromodulation in order to magnify therapeutic efficacy in the single patient. The RDoC framework with its multilevel approach constitutes the more comprehensive basis for the development of outcomes-based assessment in clinical settings that, next to the symptom assessment based on self-report measures and observed behaviors, include genetic, microbiome and neuroimaging data. The subjective dimension should become the starting point for the translation clinician, from which, thanks to the RDoC framework, delving into the neurobiological aspects of the patient.</p>
</sec>
<sec sec-type="conclusions">
<title>CONCLUSION</title>
<p>The available evidence supports understanding EO as a neurodevelopmental disorder and this implies complexities in assessment as well as opportunities in treatment.</p>
<p>In over 50% of all OCD cases, symptoms emerge during childhood or adolescence and although there is evidence that in late stages EO is a higher resistent subgroup in OCD, data suggest that an early diagnosis and treatment in EO may confer better outcomes than treatment in the general adult OCD population. Indeed, approximately one half of children with OCD experience remission of OCD symptoms with first line therapies. Despite some available clinical predictors of treatment outcome to CBT or SSRI, further studies are needed in order to identify moderators of response and further treatments once firstlines prove not to be helpful.</p>
<p>Increasing evidence suggests that the immune and glutamatergic pathways may be particularly involved in this subtype of OCD, highlighting the need for multisystemic models of the disorder and longitudinal RDoC-oriented studies, in order to detect reliable biomarkers that might go beyond the boundaries of the nervous central system. Next to studies aiming to dissect the heterogeneous OCD phenotype and identifying endophenotypes, it would be also beneficial to implement studies assessing the multimodal activities of drugs in this population, going beyond the fictitious boundaries of the old nomenclature of drugs and driving the development of a multimodal neuroscience-based therapy.</p>
<p>The existing literature supports EO as a useful diagnostic specifier of OCD and suggests the need for the fine tuning of a multimodal assessment in the individual patient that takes into account the type of onset, the immunological profile, the specific dimensions involved with particular attention towards the cognitive and motor aspect, the genetic load and the course and staging of the disorder.</p>
<p>The neurodevelopmental progression of EO indeed suggests the need for studies investigating recovery rather than resistence, and consequently implement an early, high intensity treatment approach that could multimodally combine psychotherapy, neuromodulation, psychodrugs, and immunomodulant-neuroprotective interventions.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Declared none.</p>
</ack>
<sec>
<title>Consent for Publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="competing-interests">
<title>Conflict of Interest</title>
<p>The authors declare no conflict of interest, financial or otherwise.</p>
</sec>
<ref-list>
<title>REFERENCES</title>
<ref id="r1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruscio</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>W.T.</given-names>
</name>
<name>
<surname>Kessler</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication.</article-title>
<source/>Mol. Psychiatry
          <year>2010</year>
<volume>15</volume>
<issue>1</issue>
<fpage>53</fpage>
<lpage>63</lpage>
<comment>[http://dx.doi.org/10.1038/mp.2008.94]. [PMID: 18725912].</comment>
<pub-id pub-id-type="pmid">18725912</pub-id>
</element-citation>
</ref>
<ref id="r2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olesen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gustavsson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Svensson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wittchen</surname>
<given-names>H.U.</given-names>
</name>
<name>
<surname>Jönsson</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>The economic cost of brain disorders in Europe.</article-title>
<source/>Eur. J. Neurol.
          <year>2012</year>
<volume>19</volume>
<issue>1</issue>
<fpage>155</fpage>
<lpage>162</lpage>
<comment>[http://dx.doi.org/10.1111/j.1468-1331.2011. 03590.x]. [PMID: 22175760].</comment>
<pub-id pub-id-type="pmid">22175760</pub-id>
</element-citation>
</ref>
<ref id="r3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geller</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Obsessive-compulsive and spectrum disorders in children and adolescents.</article-title>
<source/>Psychiatr. Clin. North Am.
          <year>2006</year>
<volume>29</volume>
<issue>2</issue>
<fpage>353</fpage>
<lpage>370</lpage>
<comment>[http://dx.doi.org/10.1016/j.psc.2006.02.012]. [PMID: 16650713].</comment>
<pub-id pub-id-type="pmid">16650713</pub-id>
</element-citation>
</ref>
<ref id="r4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kessler</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Berglund</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Demler</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Merikangas</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>E.E.</given-names>
</name>
</person-group>
<article-title>Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2005</year>
<volume>62</volume>
<issue>6</issue>
<fpage>593</fpage>
<lpage>602</lpage>
<comment>[http://dx.doi. org/10.1001/archpsyc.62.6.593]. [PMID: 15939837].</comment>
<pub-id pub-id-type="pmid">15939837</pub-id>
</element-citation>
</ref>
<ref id="r5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pallanti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Quercioli</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines.</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2006</year>
<volume>30</volume>
<issue>3</issue>
<fpage>400</fpage>
<lpage>412</lpage>
<comment>[http://dx.doi.org/10.1016/j.pnpbp.2005. 11.028]. [PMID: 16503369].</comment>
<pub-id pub-id-type="pmid">16503369</pub-id>
</element-citation>
</ref>
<ref id="r6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dell’Osso</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Benatti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hollander</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fineberg</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Lochner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nicolini</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lanzagorta</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Palazzo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Altamura</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Marazziti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pallanti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Van Ameringen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Karamustafalioglu</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Drummond</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Hranov</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Figee</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Zohar</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Denys</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Menchon</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS).</article-title>
<source/>Int. J. Psychiatry Clin. Pract.
          <year>2016</year>
<volume>20</volume>
<issue>4</issue>
<fpage>210</fpage>
<lpage>217</lpage>
<comment>[http://dx.doi.org/10.1080/ 13651501.2016.1207087]. [PMID: 27433835].</comment>
<pub-id pub-id-type="pmid">27433835</pub-id>
</element-citation>
</ref>
<ref id="r7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Early versus late onset obsessive-compulsive disorder: evidence for distinct subtypes.</article-title>
<source/>Clin. Psychol. Rev.
          <year>2011</year>
<volume>31</volume>
<issue>7</issue>
<fpage>1083</fpage>
<lpage>1100</lpage>
<comment>[http://dx.doi.org/10.1016/j.cpr.2011.06.007]. [PMID: 21820387].</comment>
<pub-id pub-id-type="pmid">21820387</pub-id>
</element-citation>
</ref>
<ref id="r8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grünblatt</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Oneda</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ekici</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Geissler</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Uebe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Romanos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Walitza</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>High resolution chromosomal microarray analysis in paediatric obsessive-compulsive disorder.</article-title>
<source/>BMC Med. Genomics
          <year>2017</year>
<volume>10</volume>
<issue>1</issue>
<fpage>68</fpage>
<comment>[http://dx.doi.org/ 10.1186/s12920-017-0299-5]. [PMID: 29179725].</comment>
<pub-id pub-id-type="pmid">29179725</pub-id>
</element-citation>
</ref>
<ref id="r9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stewart</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Geller</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Jenike</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pauls</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mullin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Faraone</surname>
<given-names>S.V.</given-names>
</name>
</person-group>
<article-title>Long-term outcome of pediatric obsessive-compulsive disorder: A meta-analysis and qualitative review of the literature.</article-title>
<source/>Acta Psychiatr. Scand.
          <year>2004</year>
<volume>110</volume>
<issue>1</issue>
<fpage>4</fpage>
<lpage>13</lpage>
<comment>[http://dx. doi.org/10.1111/j.1600-0447.2004.00302.x]. [PMID: 15180774].</comment>
<pub-id pub-id-type="pmid">15180774</pub-id>
</element-citation>
</ref>
<ref id="r10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fontenelle</surname>
<given-names>L.F.</given-names>
</name>
<name>
<surname>Mendlowicz</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Marques</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Versiani</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Early- and late-onset obsessive-compulsive disorder in adult patients: an exploratory clinical and therapeutic study.</article-title>
<source/>J. Psychiatr. Res.
          <year>2003</year>
<volume>37</volume>
<issue>2</issue>
<fpage>127</fpage>
<lpage>133</lpage>
<comment>[http://dx.doi.org/10.1016/S0022-3956(02)00087-0]. [PMID: 12842166].</comment>
<pub-id pub-id-type="pmid">12842166</pub-id>
</element-citation>
</ref>
<ref id="r11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grover</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kate</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Avasthi</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Factor analysis of symptom profile in early onset and late onset OCD.</article-title>
<source/>Psychiatry Res.
          <year>2017</year>
<comment>[PMID: 29033063].</comment>
</element-citation>
</ref>
<ref id="r12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delorme</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bille</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Betancur</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mathieu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chabane</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mouren-Simeoni</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Leboyer</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Exploratory analysis of obsessive compulsive symptom dimensions in children and adolescents: A prospective follow-up study.</article-title>
<source/>BMC Psychiatry
          <year>2006</year>
<volume>6</volume>
<fpage>1</fpage>
<comment>[http://dx.doi.org/10.1186/1471-244X-6-1]. [PMID: 16396684].</comment>
<pub-id pub-id-type="pmid">16396684</pub-id>
</element-citation>
</ref>
<ref id="r13">
<label>13</label>
<element-citation id="r13a" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boedhoe</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Schmaal</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ameis</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Batistuzzo</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Benedetti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Beucke</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Bollettini</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bose</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brem</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>K.I.</given-names>
</name>
<name>
<surname>Dallaspezia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Denys</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Fouche</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Giménez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gruner</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hanna</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Hibar</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Hoexter</surname>
<given-names>M.Q.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huyser</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ikari</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jahanshad</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kathmann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Lazaro</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lochner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Martínez-Zalacaín</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mataix-Cols</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Menchón</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Minuzzi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nakamae</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Narayanaswamy</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Piras</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Piras</surname>
<given-names>F.</given-names>
</name>
</person-group>
</element-citation>
<element-citation id="r13b" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pittenger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Soreni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Soriano-Mas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Spalletta</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Szeszko</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Tolin</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Venkatasubramanian</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Walitza</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>van Wingen</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>van den Heuvel</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>van den Heuvel</surname>
<given-names>O.A.</given-names>
</name>
</person-group>
<article-title>Distinct Subcortical Volume Alterations in Pediatric and Adult OCD: A worldwide meta- and mega-analysis.</article-title>
<source/>Am. J. Psychiatry
          <year>2017</year>
<volume>174</volume>
<issue>1</issue>
<fpage>60</fpage>
<lpage>69</lpage>
<comment>[http://dx.doi.org/10.1176/appi.ajp.2016.16020201]. [PMID: 27609241].</comment>
<pub-id pub-id-type="pmid">27609241</pub-id>
</element-citation>
</ref>
<ref id="r14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ivanov</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bansal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kellendonk</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sanchez-Pena</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Chakravarty</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Klahr</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Durkin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Greenhill</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>B.S.</given-names>
</name>
</person-group>
<article-title>Morphological abnormalities of the thalamus in youths with attention deficit hyperactivity disorder.</article-title>
<source/>Am. J. Psychiatry
          <year>2010</year>
<volume>167</volume>
<issue>4</issue>
<fpage>397</fpage>
<lpage>408</lpage>
<comment>[http://dx. doi.org/10.1176/appi.ajp.2009.09030398]. [PMID: 20123910].</comment>
<pub-id pub-id-type="pmid">20123910</pub-id>
</element-citation>
</ref>
<ref id="r15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Bansal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sanchez-Pena</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Sobel</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chakravarty</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Durkin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ivanov</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Plessen</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Kellendonk</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>B.S.</given-names>
</name>
</person-group>
<article-title>Enlargement of thalamic nuclei in Tourette syndrome.</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2010</year>
<volume>67</volume>
<issue>9</issue>
<fpage>955</fpage>
<lpage>964</lpage>
<comment>[http://dx.doi.org/10.1001/archgenpsychiatry.2010. 102]. [PMID: 20819989].</comment>
<pub-id pub-id-type="pmid">20819989</pub-id>
</element-citation>
</ref>
<ref id="r16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilbert</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Keshavan</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Paulson</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Narula</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mac Master</surname>
<given-names>F.P.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine.</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2000</year>
<volume>57</volume>
<issue>5</issue>
<fpage>449</fpage>
<lpage>456</lpage>
<comment>[http://dx.doi.org/10.1001/archpsyc.57.5.449]. [PMID: 10807485].</comment>
<pub-id pub-id-type="pmid">10807485</pub-id>
</element-citation>
</ref>
<ref id="r17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boileau</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>A review of obsessive-compulsive disorder in children and adolescents.</article-title>
<source/>Dialogues Clin. Neurosci.
          <year>2011</year>
<volume>13</volume>
<issue>4</issue>
<fpage>401</fpage>
<lpage>411</lpage>
<comment>[PMID: 22275846].</comment>
<pub-id pub-id-type="pmid">22275846</pub-id>
</element-citation>
</ref>
<ref id="r18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mataix-Cols</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rosario-Campos</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Leckman</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>A multidimensional model of obsessive-compulsive disorder.</article-title>
<source/>Am. J. Psychiatry
          <year>2005</year>
<volume>162</volume>
<issue>2</issue>
<fpage>228</fpage>
<lpage>238</lpage>
<comment>[http://dx.doi.org/10.1176/appi. ajp.162.2.228]. [PMID: 15677583].</comment>
<pub-id pub-id-type="pmid">15677583</pub-id>
</element-citation>
</ref>
<ref id="r19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvarenga</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Cesar</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Leckman</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Moriyama</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Bloch</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Coughlin</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Hoexter</surname>
<given-names>M.Q.</given-names>
</name>
<name>
<surname>Manfro</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Polanczyk</surname>
<given-names>G.V.</given-names>
</name>
<name>
<surname>Miguel</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>do Rosario</surname>
<given-names>M.C.</given-names>
</name>
</person-group>
<article-title>Obsessive-compulsive symptom dimensions in a population-based, cross-sectional sample of school-aged children.</article-title>
<source/>J. Psychiatr. Res.
          <year>2015</year>
<volume>62</volume>
<fpage>108</fpage>
<lpage>114</lpage>
<comment>[http://dx.doi.org/10.1016/j.jpsychires.2015.01.018]. [PMID: 25702286].</comment>
<pub-id pub-id-type="pmid">25702286</pub-id>
</element-citation>
</ref>
<ref id="r20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fullana</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Mataix-Cols</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Caspi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Harrington</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Grisham</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Moffitt</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Poulton</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Obsessions and compulsions in the community: prevalence, interference, help-seeking, developmental stability, and co-occurring psychiatric conditions.</article-title>
<source/>Am. J. Psychiatry
          <year>2009</year>
<volume>166</volume>
<issue>3</issue>
<fpage>329</fpage>
<lpage>336</lpage>
<comment>[http://dx.doi.org/10.1176/ appi.ajp.2008.08071006]. [PMID: 19188283].</comment>
<pub-id pub-id-type="pmid">19188283</pub-id>
</element-citation>
</ref>
<ref id="r21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvarenga</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>do Rosario</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Cesar</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Manfro</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Moriyama</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Bloch</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Shavitt</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Hoexter</surname>
<given-names>M.Q.</given-names>
</name>
<name>
<surname>Coughlin</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Leckman</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Miguel</surname>
<given-names>E.C.</given-names>
</name>
</person-group>
<article-title>Obsessive-compulsive symptoms are associated with psychiatric comorbidities, behavioral and clinical problems: A population-based study of Brazilian school children.</article-title>
<source/>Eur. Child Adolesc. Psychiatry
          <year>2016</year>
<volume>25</volume>
<issue>2</issue>
<fpage>175</fpage>
<lpage>182</lpage>
<comment>[http://dx.doi.org/10.1007/s00787-015-0723-3]. [PMID: 26015374].</comment>
<pub-id pub-id-type="pmid">26015374</pub-id>
</element-citation>
</ref>
<ref id="r22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dell’Osso</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Camuri</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Benatti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Buoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Altamura</surname>
<given-names>A.C.</given-names>
</name>
</person-group>
<article-title>Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: A study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder.</article-title>
<source/>Early Interv. Psychiatry
          <year>2013</year>
<volume>7</volume>
<issue>4</issue>
<fpage>374</fpage>
<lpage>380</lpage>
<comment>[http://dx.doi.org/10.1111/eip.12016]. [PMID: 23347385].</comment>
<pub-id pub-id-type="pmid">23347385</pub-id>
</element-citation>
</ref>
<ref id="r23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dell’Osso</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Buoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hollander</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Altamura</surname>
<given-names>A.C.</given-names>
</name>
</person-group>
<article-title>Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder.</article-title>
<source/>World J. Biol. Psychiatry
          <year>2010</year>
<volume>11</volume>
<issue>1</issue>
<fpage>59</fpage>
<lpage>65</lpage>
<comment>[http://dx.doi.org/10.3109/15622970903418544]. [PMID: 20001657].</comment>
<pub-id pub-id-type="pmid">20001657</pub-id>
</element-citation>
</ref>
<ref id="r24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mancebo</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Boisseau</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Garnaat</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Eisen</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Sibrava</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Stout</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Long-term course of pediatric obsessive-compulsive disorder: 3 years of prospective follow-up.</article-title>
<source/>Compr. Psychiatry
          <year>2014</year>
<volume>55</volume>
<issue>7</issue>
<fpage>1498</fpage>
<lpage>1504</lpage>
<comment>[http://dx.doi.org/10.1016/j.comppsych.2014.04.010]. [PMID: 24952937].</comment>
<pub-id pub-id-type="pmid">24952937</pub-id>
</element-citation>
</ref>
<ref id="r25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Skarphedinsson</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Skärsäter</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Haugland</surname>
<given-names>B.S.M.</given-names>
</name>
<name>
<surname>Ivarsson</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>A solid majority remit following evidence-based OCD treatments: A 3-year naturalistic outcome study in pediatric OCD.</article-title>
<source/>Eur. Child Adolesc. Psychiatry
          <year>2018</year>
<comment>[http://dx.doi.org/10.1007/ s00787-018-1137-9]. [PMID: 29502315].</comment>
</element-citation>
</ref>
<ref id="r26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hojgaard</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hybel</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Ivarsson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Skarphedinsson</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Becker Nissen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Weidle</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Melin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Torp</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Valderhaug</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>E.L.</given-names>
</name>
<name>
<surname>Compton</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lenhard</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Thomsen</surname>
<given-names>P.H.</given-names>
</name>
</person-group>
<article-title>The relevance of analogue studies for understanding obsessions and compulsions.</article-title>
<source/>Clin. Psychol. Rev.
          <year>2014</year>
<volume>34</volume>
<issue>3</issue>
<fpage>206</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="pmid">24561743</pub-id>
</element-citation>
</ref>
<ref id="r27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abramowitz</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Fabricant</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Deacon</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>McKay</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Storch</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>The relevance of analogue studies for understanding obsessions and compulsions.</article-title>
<source/>Clin. Psychol. Rev.
          <year>2014</year>
<volume>34</volume>
<issue>3</issue>
<fpage>206</fpage>
<lpage>217</lpage>
<comment>[http://dx.doi.org/10.1016/j.cpr.2014.01.004]. [PMID: 24561743].</comment>
<pub-id pub-id-type="pmid">24561743</pub-id>
</element-citation>
</ref>
<ref id="r28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zijlmans</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Marhe</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>van der Ende</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Verhulst</surname>
<given-names>F.C.</given-names>
</name>
<name>
<surname>Popma</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tiemeier</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>van den Heuvel</surname>
<given-names>O.A.</given-names>
</name>
</person-group>
<article-title>Children with Obsessive-Compulsive Symptomology in the General Population: Different Subtypes?</article-title>
<source/>J. Dev. Behav. Pediatr.
          <year>2017</year>
<volume>38</volume>
<issue>7</issue>
<fpage>476</fpage>
<lpage>482</lpage>
<comment>[http://dx. doi.org/10.1097/DBP.0000000000000467]. [PMID: 28691955].</comment>
<pub-id pub-id-type="pmid">28691955</pub-id>
</element-citation>
</ref>
<ref id="r29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Mathis</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Diniz</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Hounie</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Shavitt</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Fossaluza</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ferrão</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Leckman</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>de Bragança Pereira</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>do Rosario</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Miguel</surname>
<given-names>E.C.</given-names>
</name>
</person-group>
<article-title>Trajectory in obsessive-compulsive disorder comorbidities.</article-title>
<source/>Eur. Neuropsychopharmacol.
          <year>2013</year>
<volume>23</volume>
<issue>7</issue>
<fpage>594</fpage>
<lpage>601</lpage>
<comment>[http://dx.doi.org/10.1016/j.euroneuro.2012.08.006]. [PMID: 22921470].</comment>
<pub-id pub-id-type="pmid">22921470</pub-id>
</element-citation>
</ref>
<ref id="r30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geller</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Biederman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Faraone</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Bellordre</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Hagermoser</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cradock</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Frazier</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Coffey</surname>
<given-names>B.J.</given-names>
</name>
</person-group>
<article-title>Disentangling chronological age from age of onset in children and adolescents with obsessive-compulsive disorder.</article-title>
<source/>Int. J. Neuropsychopharmacol.
          <year>2001</year>
<volume>4</volume>
<issue>2</issue>
<fpage>169</fpage>
<lpage>178</lpage>
<comment>[http://dx.doi.org/10.1017/ S1461145701002395]. [PMID: 11466167].</comment>
<pub-id pub-id-type="pmid">11466167</pub-id>
</element-citation>
</ref>
<ref id="r31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selles</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Storch</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Lewin</surname>
<given-names>A.B.</given-names>
</name>
</person-group>
<article-title>Variations in symptom prevalence and clinical correlates in younger versus older youth with obsessive-compulsive disorder.</article-title>
<source/>Child Psychiatry Hum. Dev.
          <year>2014</year>
<volume>45</volume>
<issue>6</issue>
<fpage>666</fpage>
<lpage>674</lpage>
<comment>[http://dx.doi.org/10.1007/s10578-014-0435-9]. [PMID: 24549726].</comment>
<pub-id pub-id-type="pmid">24549726</pub-id>
</element-citation>
</ref>
<ref id="r32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abramovitch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mittelman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wilhelm</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Comorbidity between attention deficit/hyperactivity disorder and obsessive-compulsive disorder across the lifespan: A systematic and critical review.</article-title>
<source/>Harv. Rev. Psychiatry
          <year>2015</year>
<volume>23</volume>
<issue>4</issue>
<fpage>245</fpage>
<lpage>262</lpage>
<comment>[http:// dx.doi.org/10.1097/HRP.0000000000000050]. [PMID: 26052877].</comment>
<pub-id pub-id-type="pmid">26052877</pub-id>
</element-citation>
</ref>
<ref id="r33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Storch</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Merlo</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Larson</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Geffken</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Lehmkuhl</surname>
<given-names>H.D.</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>W.K.</given-names>
</name>
</person-group>
<article-title>Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder.</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2008</year>
<volume>47</volume>
<issue>5</issue>
<fpage>583</fpage>
<lpage>592</lpage>
<comment>[http://dx.doi.org/10.1097/CHI.0b013 e31816774b1]. [PMID: 18356759].</comment>
<pub-id pub-id-type="pmid">18356759</pub-id>
</element-citation>
</ref>
<ref id="r34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guzick</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>McNamara</surname>
<given-names>J.P.H.</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Balkhi</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Storch</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>W.K.</given-names>
</name>
<name>
<surname>Bussing</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Geffken</surname>
<given-names>G.R.</given-names>
</name>
</person-group>
<article-title>The link between ADHD-like inattention and obsessions and compulsions during treatment of youth with OCD.</article-title>
<source/>J. Obsessive Compuls. Relat. Disord.
          <year>2017</year>
<volume>12</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<comment>[http://dx.doi.org/10.1016/ j.jocrd.2016.11.004]. [PMID: 28966908].</comment>
<pub-id pub-id-type="pmid">28966908</pub-id>
</element-citation>
</ref>
<ref id="r35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ivarsson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Melin</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Autism spectrum traits in children and adolescents with obsessive-compulsive disorder (OCD).</article-title>
<source/>J. Anxiety Disord.
          <year>2008</year>
<volume>22</volume>
<issue>6</issue>
<fpage>969</fpage>
<lpage>978</lpage>
<comment>[http://dx.doi.org/10.1016/j.janxdis. 2007.10.003]. [PMID: 18053683].</comment>
<pub-id pub-id-type="pmid">18053683</pub-id>
</element-citation>
</ref>
<ref id="r36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stewart</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cancilliere</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wellen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sapyta</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Elevated autism spectrum disorder traits in young children with OCD.</article-title>
<source/>Child Psychiatry Hum. Dev.
          <year>2016</year>
<volume>47</volume>
<issue>6</issue>
<fpage>993</fpage>
<lpage>1001</lpage>
<comment>[http://dx.doi.org/10.1007/s10578-016-0629-4]. [PMID: 26858231].</comment>
<pub-id pub-id-type="pmid">26858231</pub-id>
</element-citation>
</ref>
<ref id="r37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsuchiyagaito</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hirano</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Asano</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Oshima</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nagaoka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takebayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Masuda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Iyo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Cognitive-behavioral therapy for obsessive-compulsive disorder with and without autism spectrum disorder: Gray matter differences associated with poor outcome.</article-title>
<source/>Front. Psychiatry
          <year>2017</year>
<volume>8</volume>
<fpage>143</fpage>
<comment>[http://dx.doi.org/10.3389/fpsyt.2017.00143]. [PMID: 28861007].</comment>
<pub-id pub-id-type="pmid">28861007</pub-id>
</element-citation>
</ref>
<ref id="r38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanidir</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Adaletli</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gunes</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kilicoglu</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Mutlu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bahali</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Aytemiz</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Uneri</surname>
<given-names>O.S.</given-names>
</name>
</person-group>
<article-title>Impact of gender, age at onset, and lifetime tic disorders on the clinical presentation and comorbidity pattern of obsessive-compulsive disorder in children and adolescents.</article-title>
<source/>J. Child Adolesc. Psychopharmacol.
          <year>2015</year>
<volume>25</volume>
<issue>5</issue>
<fpage>425</fpage>
<lpage>431</lpage>
<comment>[http://dx.doi.org/10.1089/cap.2014.0120]. [PMID: 26091196].</comment>
<pub-id pub-id-type="pmid">26091196</pub-id>
</element-citation>
</ref>
<ref id="r39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conelea</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Sapyta</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Tic-related obsessive-compulsive disorder (OCD): phenomenology and treatment outcome in the Pediatric OCD Treatment Study II.</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2014</year>
<volume>53</volume>
<issue>12</issue>
<fpage>1308</fpage>
<lpage>1316</lpage>
<comment>[http://dx.doi.org/ 10.1016/j.jaac.2014.09.014]. [PMID: 25457929].</comment>
<pub-id pub-id-type="pmid">25457929</pub-id>
</element-citation>
</ref>
<ref id="r40">
<label>40</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Ferrao</surname>
<given-names>Y.A.D.</given-names>
</name>
<name>
<surname>Alvarenga</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Hounie</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>de Mathis</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>de Rosario</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Miguel</surname>
<given-names>E.C.</given-names>
</name>
</person-group>
<source/>The phenomenology of obsessive-compulsive symptoms in Tourette Syndrome.
          <year>2013</year>
</element-citation>
</ref>
<ref id="r41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dell’Osso</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Marazziti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Pallanti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gambini</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Tundo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zanaboni</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Servello</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Scalone</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Benatti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Altamura</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Porta</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Parsing the phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary consensus.</article-title>
<source/>Int. J. Psychiatry Clin. Pract.
          <year>2017</year>
<volume>21</volume>
<issue>2</issue>
<fpage>156</fpage>
<lpage>159</lpage>
<comment>[http:// dx.doi.org/10.1080/13651501.2017.1291822]. [PMID: 28379724].</comment>
<pub-id pub-id-type="pmid">28379724</pub-id>
</element-citation>
</ref>
<ref id="r42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skarphedinsson</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Compton</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thomsen</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Weidle</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nissen</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Torp</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Hybel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Melin</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Valderhaug</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wentzel-Larsen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ivarsson</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Tics moderate sertraline, but not cognitive-behavior therapy response in pediatric obsessive-compulsive disorder patients who do not respond to cognitive-behavior therapy.</article-title>
<source/>J. Child Adolesc. Psychopharmacol.
          <year>2015</year>
<volume>25</volume>
<issue>5</issue>
<fpage>432</fpage>
<lpage>439</lpage>
<comment>[http://dx.doi.org/10.1089/cap.2014.0167]. [PMID: 26091197].</comment>
<pub-id pub-id-type="pmid">26091197</pub-id>
</element-citation>
</ref>
<ref id="r43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>March</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Foa</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder.</article-title>
<source/>Biol. Psychiatry
          <year>2007</year>
<volume>61</volume>
<issue>3</issue>
<fpage>344</fpage>
<lpage>347</lpage>
<comment>[http://dx.doi.org/10.1016/j.biopsych.2006.09.035]. [PMID: 17241830].</comment>
<pub-id pub-id-type="pmid">17241830</pub-id>
</element-citation>
</ref>
<ref id="r44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Monzani</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Leckman</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Rück</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Serlachius</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lichtenstein</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mataix-Cols</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Understanding the covariation of tics, attention-deficit/hyperactivity, and obsessive-compulsive symptoms: A population-based adult twin study.</article-title>
<source/>Am. J. Med. Genet. B. Neuropsychiatr. Genet.
          <year>2016</year>
<volume>171</volume>
<issue>7</issue>
<fpage>938</fpage>
<lpage>947</lpage>
<comment>[http:// dx.doi.org/10.1002/ajmg.b.32436]. [PMID: 26919823].</comment>
<pub-id pub-id-type="pmid">26919823</pub-id>
</element-citation>
</ref>
<ref id="r45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>O’Gorman</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>O’Kearney</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Moderators and predictors of response to cognitive behaviour therapy for pediatric obsessive-compulsive disorder: A systematic review.</article-title>
<source/>Psychiatry Res.
          <year>2018</year>
<volume>261</volume>
<fpage>50</fpage>
<lpage>60</lpage>
<comment>[http://dx.doi.org/10.1016/j.psychres.2017. 12.034]. [PMID: 29287236].</comment>
<pub-id pub-id-type="pmid">29287236</pub-id>
</element-citation>
</ref>
<ref id="r46">
<label>46</label>
<element-citation publication-type="journal">
<article-title>Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder.</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2012</year>
<volume>51</volume>
<issue>1</issue>
<fpage>98</fpage>
<lpage>113</lpage>
<comment>[http://dx.doi. org/10.1016/j.jaac.2011.09.019]. [PMID: 22176943].</comment>
<pub-id pub-id-type="pmid">22176943</pub-id>
</element-citation>
</ref>
<ref id="r47">
<label>47</label>
<element-citation publication-type="book">
<source/>In Obsessive-Compulsive Disorder, core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder.
          <publisher-loc>Leicester, UK</publisher-loc>
<year>2006</year>
</element-citation>
</ref>
<ref id="r48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varigonda</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Jakubovski</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bloch</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>Systematic review and meta-analysis: Early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder.</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2016</year>
<volume>55</volume>
<issue>10</issue>
<fpage>851</fpage>
<lpage>859</lpage>
<pub-id pub-id-type="pmid">27663940</pub-id>
</element-citation>
</ref>
<ref id="r49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>London</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Microglia and monocyte-derived macrophages: Functionally distinct populations that act in concert in CNS plasticity and repair.</article-title>
<source/>Front. Cell. Neurosci.
          <year>2013</year>
<volume>7</volume>
<fpage>34</fpage>
<comment>[http://dx.doi.org/10.3389/fncel.2013.00034]. [PMID: 23596391].</comment>
<pub-id pub-id-type="pmid">23596391</pub-id>
</element-citation>
</ref>
<ref id="r50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swedo</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Rapoport</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Cheslow</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Ayoub</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Hosier</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Wald</surname>
<given-names>E.R.</given-names>
</name>
</person-group>
<article-title>High prevalence of obsessive-compulsive symptoms in patients with Sydenham’s chorea.</article-title>
<source/>Am. J. Psychiatry
          <year>1989</year>
<volume>146</volume>
<issue>2</issue>
<fpage>246</fpage>
<lpage>249</lpage>
<comment>[http://dx.doi.org/10.1176/ ajp.146.2.246]. [PMID: 2912267].</comment>
<pub-id pub-id-type="pmid">2912267</pub-id>
</element-citation>
</ref>
<ref id="r51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swedo</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Garvey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mittleman</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Perlmutter</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lougee</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dow</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zamkoff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dubbert</surname>
<given-names>B.K.</given-names>
</name>
</person-group>
<article-title>Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases.</article-title>
<source/>Am. J. Psychiatry
          <year>1998</year>
<volume>155</volume>
<issue>2</issue>
<fpage>264</fpage>
<lpage>271</lpage>
<comment>[PMID: 9464208].</comment>
<pub-id pub-id-type="pmid">9464208</pub-id>
</element-citation>
</ref>
<ref id="r52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swedo</surname>
<given-names>S.E.L.J.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>N.R.</given-names>
</name>
</person-group>
<article-title>From Research Subgroup to Clinical
Syndrome: Modifying the PANDAS Criteria to describe PANS
(Pediatric Acute-onset Neuropsychiatric Syndrome).</article-title>
<source/>pediatr therapeut,
          <year>2012</year>
</element-citation>
</ref>
<ref id="r53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calaprice</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tona</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Parker-Athill</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>T.K.</given-names>
</name>
</person-group>
<article-title>A survey of pediatric acute-onset neuropsychiatric syndrome characteristics and course.</article-title>
<source/>J. Child Adolesc. Psychopharmacol.
          <year>2017</year>
<volume>27</volume>
<issue>7</issue>
<fpage>607</fpage>
<lpage>618</lpage>
<comment>[PMID: 28140619].</comment>
<pub-id pub-id-type="pmid">28140619</pub-id>
</element-citation>
</ref>
<ref id="r54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiarello</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Spitoni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hollander</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Matucci Cerinic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pallanti</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>An expert opinion on PANDAS/PANS: Highlights and controversies.</article-title>
<source/>Int. J. Psychiatry Clin. Pract.
          <year>2017</year>
<volume>21</volume>
<issue>2</issue>
<fpage>91</fpage>
<lpage>98</lpage>
<comment>[http:// dx.doi.org/10.1080/13651501.2017.1285941]. [PMID: 28498087].</comment>
<pub-id pub-id-type="pmid">28498087</pub-id>
</element-citation>
</ref>
<ref id="r55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teixeira</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Marques</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Miguel</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Fontenelle</surname>
<given-names>L.F.</given-names>
</name>
</person-group>
<article-title>Searching for the immune basis of obsessive-compulsive disorder.</article-title>
<source/>Neuroimmunomodulation
          <year>2014</year>
<volume>21</volume>
<issue>2-3</issue>
<fpage>152</fpage>
<lpage>158</lpage>
<comment>[http://dx.doi.org/10.1159/000356554]. [PMID: 24557049].</comment>
<pub-id pub-id-type="pmid">24557049</pub-id>
</element-citation>
</ref>
<ref id="r56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Attwells</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Setiawan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Rusjan</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Mizrahi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Miler</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Richter</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kish</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Houle</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ravindran</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Inflammation in the neurocircuitry of obsessive-compulsive disorder.</article-title>
<source/>JAMA Psychiatry
          <year>2017</year>
<volume>74</volume>
<issue>8</issue>
<fpage>833</fpage>
<lpage>840</lpage>
<comment>[http://dx.doi.org/10.1001/jamapsychiatry.2017.1567]. [PMID: 28636705].</comment>
<pub-id pub-id-type="pmid">28636705</pub-id>
</element-citation>
</ref>
<ref id="r57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Réus</surname>
<given-names>G.Z.</given-names>
</name>
<name>
<surname>Fries</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Stertz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Badawy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Passos</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Barichello</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kapczinski</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Quevedo</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders.</article-title>
<source/>Neuroscience
          <year>2015</year>
<volume>300</volume>
<fpage>141</fpage>
<lpage>154</lpage>
<comment>[http://dx.doi.org/ 10.1016/j.neuroscience.2015.05.018]. [PMID: 25981208].</comment>
<pub-id pub-id-type="pmid">25981208</pub-id>
</element-citation>
</ref>
<ref id="r58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frick</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pittenger</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Microglial dysregulation in psychiatric disease.</article-title>
<source/>Clin. Dev. Immunol.
          <year>2013</year>
<volume>2013</volume>
<elocation-id>608654</elocation-id>
<comment>[http://dx.doi.org/10.1155/2013/608654]. [PMID: 23690824].</comment>
<pub-id pub-id-type="pmid">23690824</pub-id>
</element-citation>
</ref>
<ref id="r59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amantea</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bagetta</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Drug repurposing for immune modulation in acute ischemic stroke.</article-title>
<source/>Curr. Opin. Pharmacol.
          <year>2016</year>
<volume>26</volume>
<fpage>124</fpage>
<lpage>130</lpage>
<comment>[http://dx.doi.org/10.1016/j.coph.2015.11.006]. [PMID: 26657075].</comment>
<pub-id pub-id-type="pmid">26657075</pub-id>
</element-citation>
</ref>
<ref id="r60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burchi</surname>
<given-names>E.P.S.</given-names>
</name>
</person-group>
<article-title>Antibiotics for PANDAS? Limited evidence. Review and putative mechanisms of action.</article-title>
<source/>Prim Care Companion CNS
          <comment>in press</comment>
</element-citation>
</ref>
<ref id="r61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stock</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Fiedler</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Acharya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lange</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Mlynarczyk</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>McCormack</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Kanuri</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Kondru</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Brewer</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Antibiotics acting as neuroprotectants <italic>via</italic> mechanisms independent of their anti-infective activities.</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<volume>73</volume>
<fpage>174</fpage>
<lpage>182</lpage>
<comment>[http://dx.doi.org/ 10.1016/j.neuropharm.2013.04.059]. [PMID: 23748053].</comment>
<pub-id pub-id-type="pmid">23748053</pub-id>
</element-citation>
</ref>
<ref id="r62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothstein</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Haenggeli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Bergles</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dykes Hoberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vidensky</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Toan</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Bruijn</surname>
<given-names>L.I.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Z.Z.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>P.B.</given-names>
</name>
</person-group>
<article-title>Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.</article-title>
<source/>Nature
          <year>2005</year>
<volume>433</volume>
<issue>7021</issue>
<fpage>73</fpage>
<lpage>77</lpage>
<comment>[http://dx.doi.org/10.1038/nature03180]. [PMID: 15635412].</comment>
<pub-id pub-id-type="pmid">15635412</pub-id>
</element-citation>
</ref>
<ref id="r63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shmelkov</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Hormigo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Proenca</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Bath</surname>
<given-names>K.G.</given-names>
</name>
<name>
<surname>Milde</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shmelkov</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kushner</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Baljevic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dincheva</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Valenzuela</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Gale</surname>
<given-names>N.W.</given-names>
</name>
<name>
<surname>Yancopoulos</surname>
<given-names>G.D.</given-names>
</name>
<name>
<surname>Ninan</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Rafii</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice.</article-title>
<source/>Nat. Med.
          <year>2010</year>
<volume>16</volume>
<issue>5</issue>
<fpage>598</fpage>
<lpage>602</lpage>
<comment>[http://dx. doi.org/10.1038/nm.2125].</comment>
<pub-id pub-id-type="pmid">20418887</pub-id>
</element-citation>
</ref>
<ref id="r64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Welch</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rodriguiz</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Trotta</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Peca</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Feliciano</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dudek</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Calakos</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wetsel</surname>
<given-names>W.C.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice.</article-title>
<source/>Nature
          <year>2007</year>
<volume>448</volume>
<issue>7156</issue>
<fpage>894</fpage>
<lpage>900</lpage>
<comment>[http://dx.doi.org/ 10.1038/nature06104]. [PMID: 17713528].</comment>
<pub-id pub-id-type="pmid">17713528</pub-id>
</element-citation>
</ref>
<ref id="r65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stewart</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Mayerfeld</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Crane</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>O’Dushlaine</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fagerness</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Scharf</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kassam</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Moya</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Wendland</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Delorme</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Richter</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Veenstra-VanderWeele</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Samuels</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>McCracken</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Fyer</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Riddle</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Grados</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Bienvenu</surname>
<given-names>O.J.</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shugart</surname>
<given-names>Y.Y.</given-names>
</name>
<name>
<surname>Piacentini</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nestadt</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Jenike</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>E.H.</given-names>
</name>
<name>
<surname>Pauls</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Hanna</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Mathews</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Meta-analysis of association between obsessive-compulsive disorder and the 3′ region of neuronal glutamate transporter gene SLC1A1.</article-title>
<source/>Am. J. Med. Genet. B. Neuropsychiatr. Genet.
          <year>2013</year>
<volume>162B</volume>
<issue>4</issue>
<fpage>367</fpage>
<lpage>379</lpage>
<comment>[http://dx.doi.org/10.1002/ajmg.b. 32137]. [PMID: 23606572].</comment>
<pub-id pub-id-type="pmid">23606572</pub-id>
</element-citation>
</ref>
<ref id="r66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alonso</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gratacós</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Segalàs</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Escaramís</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Real</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bayés</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Labad</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>López-Solà</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Estivill</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Menchón</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Association between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorder.</article-title>
<source/>J. Psychiatry Neurosci.
          <year>2012</year>
<volume>37</volume>
<issue>4</issue>
<fpage>273</fpage>
<lpage>281</lpage>
<comment>[http://dx.doi.org/10.1503/jpn.110109]. [PMID: 22433450].</comment>
<pub-id pub-id-type="pmid">22433450</pub-id>
</element-citation>
</ref>
<ref id="r67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirschtritt</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Bloch</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Mathews</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Obsessive-compulsive disorder: Advances in diagnosis and treatment.</article-title>
<source/>JAMA
          <year>2017</year>
<volume>317</volume>
<issue>13</issue>
<fpage>1358</fpage>
<lpage>1367</lpage>
<comment>[http://dx.doi.org/10.1001/jama. 2017.2200]. [PMID: 28384832].</comment>
<pub-id pub-id-type="pmid">28384832</pub-id>
</element-citation>
</ref>
<ref id="r68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laoutidis</surname>
<given-names>Z.G.</given-names>
</name>
<name>
<surname>Lekka</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Kioulos</surname>
<given-names>K.T.</given-names>
</name>
</person-group>
<article-title>Glutamatergic agents as add-on medication for the treatment of obsessive-compulsive disorder: A systematic review and meta-analysis.</article-title>
<source/>J. Clin. Psychiatry
          <year>2016</year>
<volume>77</volume>
<issue>12</issue>
<fpage>e1576</fpage>
<lpage>e1583</lpage>
<comment>[http://dx.doi.org/10.4088/ JCP.15r10164]. [PMID: 27780337].</comment>
<pub-id pub-id-type="pmid">27780337</pub-id>
</element-citation>
</ref>
<ref id="r69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Neill</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Piacentini</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ly</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Bergman</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rozenman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peris</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vreeland</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mudgway</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Salamon</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Posse</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hellemann</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Alger</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>McCracken</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Nurmi</surname>
<given-names>E.L.</given-names>
</name>
</person-group>
<article-title>Glutamate in pediatric obsessive-compulsive disorder and response to cognitive-behavioral therapy: Randomized clinical triaL.</article-title>
<source/>Neuropsychopharmacology
          <year>2017</year>
<volume>42</volume>
<issue>12</issue>
<fpage>2414</fpage>
<lpage>2422</lpage>
<comment>[http://dx.doi.org/10.1038/npp.2017.77]. [PMID: 28409563].</comment>
<pub-id pub-id-type="pmid">28409563</pub-id>
</element-citation>
</ref>
<ref id="r70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grant</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Luckenbaugh</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Lougee</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Zarate</surname>
<given-names>C.A.</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Swedo</surname>
<given-names>S.E.</given-names>
</name>
</person-group>
<article-title>12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.</article-title>
<source/>Neuropsychopharmacology
          <year>2014</year>
<volume>39</volume>
<issue>6</issue>
<fpage>1453</fpage>
<lpage>1459</lpage>
<comment>[http://dx.doi.org/10.1038/npp.2013.343]. [PMID: 24356715].</comment>
<pub-id pub-id-type="pmid">24356715</pub-id>
</element-citation>
</ref>
<ref id="r71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Storch</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Wilhelm</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sprich</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Henin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Micco</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mutch</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Lewin</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Geller</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Efficacy of augmentation of cognitive behavior therapy with weight-adjusted d-cycloserine <italic>vs</italic>. placebo in pediatric obsessive-compulsive disorder: A randomized clinical trial.</article-title>
<source/>JAMA Psychiatry
          <year>2016</year>
<volume>73</volume>
<issue>8</issue>
<fpage>779</fpage>
<lpage>788</lpage>
<comment>[http://dx.doi.org/10.1001/jamapsychiatry. 2016.1128]. [PMID: 27367832].</comment>
<pub-id pub-id-type="pmid">27367832</pub-id>
</element-citation>
</ref>
<ref id="r72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghanizadeh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mohammadi</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Bahraini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Keshavarzi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Firoozabadi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alavi Shoshtari</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Efficacy of N-acetylcysteine augmentation on obsessive compulsive disorder: A multicenter randomized double blind placebo controlled clinical trial.</article-title>
<source/>Iran. J. Psychiatry
          <year>2017</year>
<volume>12</volume>
<issue>2</issue>
<fpage>134</fpage>
<lpage>141</lpage>
<comment>[PMID: 28659986].</comment>
<pub-id pub-id-type="pmid">28659986</pub-id>
</element-citation>
</ref>
<ref id="r73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mechler</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Häge</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schweinfurth</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Glennon</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Dijkhuizen</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Durston</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Buitelaar</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Banaschewski</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dittmann</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<collab>Tactics Consortium</collab>
<article-title>T. Glutamatergic agents in the treatment of compulsivity and impulsivity in child and adolescent psychiatry: A systematic review of the literature.</article-title>
<source/>Z. Kinder Jugendpsychiatr. Psychother.
          <year>2018</year>
<volume>46</volume>
<issue>3</issue>
<fpage>246</fpage>
<lpage>263</lpage>
<comment>[http://dx.doi.org/10.1024/1422-4917/a000546]. [PMID: 28922069].</comment>
<pub-id pub-id-type="pmid">28922069</pub-id>
</element-citation>
</ref>
<ref id="r74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasquini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Biondi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Memantine augmentation for refractory obsessive-compulsive disorder.</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2006</year>
<volume>30</volume>
<issue>6</issue>
<fpage>1173</fpage>
<lpage>1175</lpage>
<comment>[http://dx.doi.org/10. 1016/j.pnpbp.2006.04.013]. [PMID: 16730870].</comment>
<pub-id pub-id-type="pmid">16730870</pub-id>
</element-citation>
</ref>
<ref id="r75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez</surname>
<given-names>C.I.</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>J.</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Marcus</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Snape</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rynn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>H.B.</given-names>
</name>
</person-group>
<article-title>Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial.</article-title>
<source/>J. Clin. Psychiatry
          <year>2010</year>
<volume>71</volume>
<issue>9</issue>
<fpage>1247</fpage>
<lpage>1249</lpage>
<comment>[http://dx.doi.org/10.4088/JCP. 09l05805blu]. [PMID: 20923629].</comment>
<pub-id pub-id-type="pmid">20923629</pub-id>
</element-citation>
</ref>
<ref id="r76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dean</surname>
<given-names>O.M.</given-names>
</name>
<name>
<surname>Data-Franco</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Giorlando</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Minocycline: therapeutic potential in psychiatry.</article-title>
<source/>CNS Drugs
          <year>2012</year>
<volume>26</volume>
<issue>5</issue>
<fpage>391</fpage>
<lpage>401</lpage>
<comment>[http://dx.doi.org/10.2165/11632000-000000000-00000]. [PMID: 22486246].</comment>
<pub-id pub-id-type="pmid">22486246</pub-id>
</element-citation>
</ref>
<ref id="r77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakrabarty</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bhattacharyya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Christopher</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Glutamatergic dysfunction in OCD.</article-title>
<source/>Neuropsychopharmacology
          <year>2005</year>
<volume>30</volume>
<issue>9</issue>
<fpage>1735</fpage>
<lpage>1740</lpage>
<comment>[http://dx.doi.org/10.1038/sj.npp.1300733]. [PMID: 15841109].</comment>
<pub-id pub-id-type="pmid">15841109</pub-id>
</element-citation>
</ref>
<ref id="r78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>N.P.</given-names>
</name>
<name>
<surname>Venkatasubramanian</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ravi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kalmady</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cherian</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yc</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Plasma cytokine abnormalities in drug-naïve, comorbidity-free obsessive-compulsive disorder.</article-title>
<source/>Psychiatry Res.
          <year>2015</year>
<volume>229</volume>
<issue>3</issue>
<fpage>949</fpage>
<lpage>952</lpage>
<comment>[http://dx.doi.org/10.1016/j.psychres. 2015.07.009]. [PMID: 26187339].</comment>
<pub-id pub-id-type="pmid">26187339</pub-id>
</element-citation>
</ref>
<ref id="r79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Çolak Sivri</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bilgiç</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kılınç</surname>
<given-names>İ.</given-names>
</name>
</person-group>
<article-title>Cytokine, chemokine and BDNF levels in medication-free pediatric patients with obsessive-compulsive disorder.</article-title>
<source/>Eur. Child Adolesc. Psychiatry
          <year>2018</year>
<comment>[PMID: 29302747].</comment>
</element-citation>
</ref>
<ref id="r80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodríguez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Morer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>González-Navarro</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Serra-Pages</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Boloc</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>García-Cerro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gassó</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lázaro</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Inflammatory dysregulation of monocytes in pediatric patients with obsessive-compulsive disorder.</article-title>
<source/>J. Neuroinflammation
          <year>2017</year>
<volume>14</volume>
<issue>1</issue>
<fpage>261</fpage>
<comment>[http://dx.doi.org/10.1186/s12974-017-1042-z]. [PMID: 29284508].</comment>
<pub-id pub-id-type="pmid">29284508</pub-id>
</element-citation>
</ref>
<ref id="r81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nazimek</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Strobel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bryniarski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kozlowski</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Filipczak-Bryniarska</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bryniarski</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>The role of macrophages in anti-inflammatory activity of antidepressant drugs.</article-title>
<source/>Immunobiology
          <year>2017</year>
<volume>222</volume>
<issue>6</issue>
<fpage>823</fpage>
<lpage>830</lpage>
<comment>[http://dx.doi.org/10.1016/j.imbio.2016.07. 001]. [PMID: 27453459].</comment>
<pub-id pub-id-type="pmid">27453459</pub-id>
</element-citation>
</ref>
<ref id="r82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gobin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Van Steendam</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Denys</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Deforce</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Selective serotonin reuptake inhibitors as a novel class of immunosuppressants.</article-title>
<source/>Int. Immunopharmacol.
          <year>2014</year>
<volume>20</volume>
<issue>1</issue>
<fpage>148</fpage>
<lpage>156</lpage>
<comment>[http://dx.doi. org/10.1016/j.intimp.2014.02.030]. [PMID: 24613205].</comment>
<pub-id pub-id-type="pmid">24613205</pub-id>
</element-citation>
</ref>
<ref id="r83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gałecki</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mossakowska-Wójcik</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Talarowska</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The anti-inflammatory mechanism of antidepressants - SSRIs, SNRIs.</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2018</year>
<volume>80</volume>
<issue>Pt C</issue>
<fpage>291</fpage>
<lpage>294</lpage>
<comment>[http://dx.doi.org/10.1016/j.pnpbp.2017.03.016]. [PMID: 28342944].</comment>
<pub-id pub-id-type="pmid">28342944</pub-id>
</element-citation>
</ref>
<ref id="r84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alboni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Poggini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Garofalo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Milior</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>El Hajj</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lecours</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Girard</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gagnon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Boisjoly-Villeneuve</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brunello</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wolfer</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Limatola</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Maggi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Branchi</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Fluoxetine treatment affects the inflammatory response and microglial function according to the quality of the living environment.</article-title>
<source/>Brain Behav. Immun.
          <year>2016</year>
<volume>58</volume>
<fpage>261</fpage>
<lpage>271</lpage>
<comment>[http://dx.doi. org/10.1016/j.bbi.2016.07.155]. [PMID: 27474084].</comment>
<pub-id pub-id-type="pmid">27474084</pub-id>
</element-citation>
</ref>
<ref id="r85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Narayan</surname>
<given-names>V.A.</given-names>
</name>
<name>
<surname>Wittenberg</surname>
<given-names>G.M.</given-names>
</name>
</person-group>
<article-title>Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders.</article-title>
<source/>BMC Pharmacol. Toxicol.
          <year>2016</year>
<volume>17</volume>
<issue>1</issue>
<fpage>47</fpage>
<comment>[http://dx.doi.org/ 10.1186/s40360-016-0090-9]. [PMID: 27765060].</comment>
<pub-id pub-id-type="pmid">27765060</pub-id>
</element-citation>
</ref>
<ref id="r86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sayyah</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Boostani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pakseresht</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Malayeri</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder.</article-title>
<source/>Psychiatry Res.
          <year>2011</year>
<volume>189</volume>
<issue>3</issue>
<fpage>403</fpage>
<lpage>406</lpage>
<comment>[http://dx.doi.org/ 10.1016/j.psychres.2011.01.019]. [PMID: 21329988].</comment>
<pub-id pub-id-type="pmid">21329988</pub-id>
</element-citation>
</ref>
<ref id="r87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shalbafan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mohammadinejad</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shariat</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Alavi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zeinoddini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salehi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Askari</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Akhondzadeh</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: A double-blind, placebo-controlled, randomized trial.</article-title>
<source/>Pharmacopsychiatry
          <year>2015</year>
<volume>48</volume>
<issue>4-5</issue>
<fpage>136</fpage>
<lpage>140</lpage>
<comment>[PMID: 25959196].</comment>
<pub-id pub-id-type="pmid">25959196</pub-id>
</element-citation>
</ref>
<ref id="r88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strauss</surname>
<given-names>K.I.</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Cyclooxygenase-2 inhibition protects cultured cerebellar granule neurons from glutamate-mediated cell death.</article-title>
<source/>J. Neurotrauma
          <year>2002</year>
<volume>19</volume>
<issue>5</issue>
<fpage>627</fpage>
<lpage>638</lpage>
<comment>[http://dx.doi.org/ 10.1089/089771502753754091]. [PMID: 12042097].</comment>
<pub-id pub-id-type="pmid">12042097</pub-id>
</element-citation>
</ref>
<ref id="r89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borre</surname>
<given-names>Y.E.</given-names>
</name>
<name>
<surname>Moloney</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>The impact of microbiota on brain and behavior: Mechanisms &amp; therapeutic potential.</article-title>
<source/>Adv. Exp. Med. Biol.
          <year>2014</year>
<volume>817</volume>
<fpage>373</fpage>
<lpage>403</lpage>
<comment>[http://dx.doi.org/10.1007/978-1-4939-0897-4_17]. [PMID: 24997043].</comment>
<pub-id pub-id-type="pmid">24997043</pub-id>
</element-citation>
</ref>
<ref id="r90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cenit</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Sanz</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Codoñer-Franch</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Influence of gut microbiota on neuropsychiatric disorders.</article-title>
<source/>World J. Gastroenterol.
          <year>2017</year>
<volume>23</volume>
<issue>30</issue>
<fpage>5486</fpage>
<lpage>5498</lpage>
<comment>[http://dx.doi.org/10.3748/wjg.v23.i30.5486]. [PMID: 28852308].</comment>
<pub-id pub-id-type="pmid">28852308</pub-id>
</element-citation>
</ref>
<ref id="r91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burokas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arboleya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moloney</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Stanton</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Targeting the microbiota-gut-brain axis: Prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice.</article-title>
<source/>Biol. Psychiatry
          <year>2017</year>
<volume>82</volume>
<issue>7</issue>
<fpage>472</fpage>
<lpage>487</lpage>
<comment>[http:// dx.doi.org/10.1016/j.biopsych.2016.12.031]. [PMID: 28242013].</comment>
<pub-id pub-id-type="pmid">28242013</pub-id>
</element-citation>
</ref>
<ref id="r92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turna</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grosman</surname>
<given-names>K.K.</given-names>
</name>
<name>
<surname>Anglin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Van Ameringen</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>“What’s bugging the gut in Ocd?” a review of the gut microbiome in obsessive-compulsive disorder.</article-title>
<source/>Depress. Anxiety
          <year>2016</year>
<volume>33</volume>
<issue>3</issue>
<fpage>171</fpage>
<lpage>178</lpage>
<comment>[http://dx.doi.org/10.1002/da.22454]. [PMID: 26629974].</comment>
<pub-id pub-id-type="pmid">26629974</pub-id>
</element-citation>
</ref>
<ref id="r93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kantak</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Bobrow</surname>
<given-names>D.N.</given-names>
</name>
<name>
<surname>Nyby</surname>
<given-names>J.G.</given-names>
</name>
</person-group>
<article-title>Obsessive-compulsive-like behaviors in house mice are attenuated by a probiotic (Lactobacillus rhamnosus GG).</article-title>
<source/>Behav. Pharmacol.
          <year>2014</year>
<volume>25</volume>
<issue>1</issue>
<fpage>71</fpage>
<lpage>79</lpage>
<comment>[http://dx.doi.org/10.1097/FBP.0000000000000013]. [PMID: 24257436].</comment>
<pub-id pub-id-type="pmid">24257436</pub-id>
</element-citation>
</ref>
<ref id="r94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Insel</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cuthbert</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Garvey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Heinssen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pine</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sanislow</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders.</article-title>
<source/>Am. J. Psychiatry
          <year>2010</year>
<volume>167</volume>
<issue>7</issue>
<fpage>748</fpage>
<lpage>751</lpage>
<comment>[http:// dx.doi.org/10.1176/appi.ajp.2010.09091379]. [PMID: 20595427].</comment>
<pub-id pub-id-type="pmid">20595427</pub-id>
</element-citation>
</ref>
<ref id="r95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valentin</surname>
<given-names>V.V.</given-names>
</name>
<name>
<surname>Dickinson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>O’Doherty</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Determining the neural substrates of goal-directed learning in the human brain.</article-title>
<source/>J. Neurosci.
          <year>2007</year>
<volume>27</volume>
<issue>15</issue>
<fpage>4019</fpage>
<lpage>4026</lpage>
<comment>[http://dx.doi.org/10.1523/ JNEUROSCI.0564-07.2007]. [PMID: 17428979].</comment>
<pub-id pub-id-type="pmid">17428979</pub-id>
</element-citation>
</ref>
<ref id="r96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmari</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Dougherty</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Dissecting Ocd Circuits: From animal models to targeted treatments.</article-title>
<source/>Depress. Anxiety
          <year>2015</year>
<volume>32</volume>
<issue>8</issue>
<fpage>550</fpage>
<lpage>562</lpage>
<comment>[http://dx.doi.org/10.1002/da.22367]. [PMID: 25952989].</comment>
<pub-id pub-id-type="pmid">25952989</pub-id>
</element-citation>
</ref>
<ref id="r97">
<label>97</label>
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Brennan</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Use of an Individual-Level Approach to Identify Cortical
Connectivity Biomarkers of Global and Dimen- sional Symptom
Severity and Improvement in Obsessive-Compulsive Disorder.</article-title>
<source/>ACNP 56th Annual Meeting,Poster session.
        </element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<title>Clinical moderators and predictors of response to SSRIs and CBT in pediatric OCD.</title>
</caption>
<table frame="border" rules="all" width="100%">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">First Line Treatments for Pediatric OCD</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Clinical Moderators of Response</bold>
</th>
<th align="center" colspan="1" rowspan="1" scope="col" valign="top">
<bold>Clinical Predictors of Response</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">CBT</td>
<td align="center" colspan="1" rowspan="1" valign="top">family history [<xref ref-type="bibr" rid="r45">45</xref>]</td>
<td align="center" colspan="1" rowspan="1" valign="top">Severity; anxiety and depressive symptoms; ADHD; ASD [<xref ref-type="bibr" rid="r33">33</xref>, <xref ref-type="bibr" rid="r45">45</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" scope="row" valign="top">SSRI</td>
<td align="center" colspan="1" rowspan="1" valign="top">Tics [<xref ref-type="bibr" rid="r45">45</xref>]; Early improvements (2weeks) [<xref ref-type="bibr" rid="r48">48</xref>]</td>
<td align="center" colspan="1" rowspan="1" valign="top">Severity; anxiety and depressive symptoms [<xref ref-type="bibr" rid="r45">45</xref>, <xref ref-type="bibr" rid="r48">48</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>